SKOKIE, Ill., July 23, 2014 /PRNewswire/ -- AuraSense Therapeutics, the pioneer in developing spherical nucleic acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, announced today that David Snyder has joined AuraSense Therapeutics' executive leadership team as chief financial officer effective July 11.
Prior to joining AuraSense Therapeutics, Mr. Snyder was Executive Vice President and Chief Financial Officer of Cellular Dynamics International Inc., where he was responsible for all financial functions, human resources, and general administration. Snyder helped lead CDI's successful IPO in July of 2013. He previously served as senior vice president of finance, site vice president and chief financial officer of Roche NimbleGen from 2007 to 2008. From 2006 to 2007, he served as vice president and chief financial officer of NimbleGen Systems, Inc. Prior to NimbleGen, Mr. Snyder held various leadership positions in software, real estate, and diversified manufacturing industries. He has served as a director of Invenra, Inc. since 2012. He has also served on the Board of Trustees of Ottawa University since 2012. Mr. Snyder received a B.A., summa cum laude, from Ottawa University and an MBA with high honors from the Harvard Business School, where he was designated a George Fisher Baker Scholar.
About AuraSense Therapeutics, LLC
AuraSense Therapeutics (AST) is a biopharmaceutical company developing first-in-class therapies based upon its proprietary Spherical Nucleic Acid (SNA™) gene regulation and immune modulation strategies. AST is leading the translation of SNA constructs as innovative medicines with a core focus on debilitating diseases with limited or no treatment options. AuraSense Therapeutics' uniquely engineered SNA™ constructs possess attractive biocompatibility and versatility as therapeutics and hold great promise for combating the most life-threatening diseases, including many forms of cancer, infectious disease, and skin conditions.
About Spherical Nucleic Acids
SNA™ technology originated in the lab of Professor Chad A. Mirkin at the Northwestern University International Institute for Nanotechnology. SNAs are nanoscale particles that consist of a spherical arrangement of densely packed and radially oriented nucleic acids. This architecture overcomes one of the most difficult obstacles to gene regulation: safe and effective delivery into cells and tissues of therapeutic importance without the need for additional physical or chemical methods or components. The SNAs can be designed to be extremely potent and highly targeted gene regulation and immune-modulatory agents.
SOURCE AuraSense Therapeutics, LLC